Finally, combination therapies targeting both CXCL13+ CD8+ T cells and CAFs/Treg cells could also be considered to overcome the clinical challenges of acquired resistance in the HRD population and the limited efficacy of PARPi and anti‐PDCD1 combination therapy. This evidence concerns the gene CD8A and hypoparathyroidism-retardation-dysmorphism syndrome.